
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Considering participation in a clinical trial is often a very difficult decision for patients, especially those dealing with a rare disease.
Considering participation in a clinical trial is often a very difficult decision for patients, especially those dealing with a rare disease. In this
The video features expert insights from:
This video is one of several featured in the CLF’s Online Learning Center. Other topics include recommendations for managing itch and a three-part overview of treatments for cutaneous lymphoma.
For more information, visit






